Antineoplastic cyclic astin analogues kill tumour cells via caspase-mediated induction of apoptosis

Carcinogenesis

Volumn 26, Issue 4, 2005, Pages 733-739

  Cozzolino, Rosanna ^a   Palladino, Pasquale ^a   Rossi, Filomena ^a   Calì, Gaetano ^a   Benedetti, Ettore ^a   Laccetti, Paolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASTIN 3; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYLFLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMYLHISTIDYLASPARTYLFLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLASPARTYLFLUOROMETHYL KETONE; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; UNCLASSIFIED DRUG; ASTIN B; CASPASE; CYCLOPEPTIDE; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR CELL; ASTERACEAE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTER PLANT; CARCINOMA, PAPILLARY; CASPASES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; PEPTIDES, CYCLIC; THYROID NEOPLASMS;

EID: 17844389613     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgi017     Document Type: Article

References (36)

1. Morita, H., Nagashima, S., Takeya, K., Itokawa, H. and Iitaka, Y. (1995) Structures and conformation of antitumor cyclic pentapeptides, astin A, B and C, from Aster tataricus. Tetrahedron, 51, 1121-1132.
2. Morita, H., Nagashima, S., Yuki, U., Takeya, K. and Itokawa, H. (1993) Astin A and B, antitumor cyclic pentapeptides from Aster tataricus. Chem. Pharm. Bull., 41, 992-993.
3. Morita, H., Nagashima, S., Yuki, U., Takeya, K. and Itokawa, H. (1996) Cyclic peptides from higher plants. XXVIII. Antitumor activity and hepatic microsomal biotransformation of cyclic pentapeptides, astins, from Aster tataricus. Chem. Pharm. Bull., 44, 1026-1032.
4. Itokawa, H., Takeya, K., Hitotsuyanagi, Y. and Morita, H. (2000) Antitumor compounds isolated from higher plants. J. Biochem. Mol. Biol. Biophys., 4, 213-222.
5. Morita, H., Nagashima, S., Takeya, K. and Itokawa, H. (1995) Structure of a new peptide, astin J, from Aster tataricus. Chem. Pharm. Bull., 43, 271-273.
6. Rossi, F., Zanotti, G., Saviano, M., Iacovino, R., Palladino, P., Saviano, G., Amodeo, P., Tancredi, T., Laccetti, P., Corbier, C. and Benedetti, E. (2004) New antitumor cyclic astin analogues: synthesis, conformation and bioactivity. J. Pept. Sci., 10, 92-102.
7. Vesely, B.A., McAfee, Q., Gower, W.R. and Vesely, D.L. (2003). Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur. J. Clin. Invest., 33, 998-1006.
8. Johnstone, R.W., Ruefli, A.A. and Lowe, S.W. (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108, 153-164.
9. Wolf, B.B. and Green, D.R. (1999) Suicidal tendencies: apoptotic cell death by caspase family proteinases. J. Biol. Chem., 274, 20049-20052.
10. Cryns, V. and Yuan, J. (1998) Proteases to die for. Genes Dev., 12, 1551-1570.
11. Budihardjo, I., Oliver, H., Lutter, M., Luo, X. and Wang, X. (1999) Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 15, 269-290.
12. Thornberry, N.A. and Lazebnik, Y. (1998) Caspases: enemies within. Science, 281, 1312-1316.
13. Earnshaw, W.C., Martins, I.M. and Kaufmann, S.H. (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem., 68, 383-424.
14. Fagin, J.A., Matscio, K., Karmakar, A., Chen, D.L., Tang, S.H. and Koeffler, H.P. (1993) High prevalence of mutation of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest., 91, 179-184.
15. Ain, K.B., Tofiq, S. and Taylor, K.D. (1996) Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J. Clin. Endocrinol. Metab., 81, 3650-3653.
16. De Lorenzo, C., Palmer, D.B., Piccoli, R., Ritter, M.A. and D'Alessio, G. (2002) A new human antitumor immunoreagent specific for ErbB2. Clin. Cancer Res., 8, 1710-1719.
17. Carmichael, J., De Graff, W.G., Gazdar, A.F., Minna, J.D. and Mitchell, J.B. (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47, 936-942.
18. Denizot, F. and Lang, R. (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods, 89, 271-277.
19. Dedoussis, G.V.Z., Mouzaki, A., Theodoropoulou, M., Menounos, P., Kyrtsonis, M.C., Karameris, A. and Maniatis, A. (1999) Endogenous interleukin 6 conveys resistances to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line. Exp. Cell Res., 249, 269-278.
20. Vermes, I., Haanen, C., Steffens-Nakken, H. and Retelingsperger, M. (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods., 184, 39-51.
21. Aubry, J.P., Caron, A.G., Moine, V. and Bonnefoy, J.Y. (1999) Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry, 37, 197-204.
22. Catchpoole, D.R. and Stewart, B.W. (1993) Etoposide-induced cytotoxicity in two human T-cell leukemic lines: delayed loss of membrane permeability rather than DNA fragmentation as an indicator of programmed cell death. Cancer Res., 53, 4287-4296.
23. Boccellino, M., Cuccovillo, F., Napolitano, M., Sannolo, N., Balestrieri, C., Acampora, A., Giovane, A. and Quagliuolo, L. (2003) Styrene-7, 8-oxide activates a complex apoptotic response in neuronal PC12 cell line. Carcinogenesis, 24, 535-540.
24. Lowe, S.W. and Lin, A.W. (2000) Apoptosis in cancer. Carcinogenesis, 21, 485-495.
25. Kerr, J.F.R. (2002). History of the events leading to the formulation of the apoptosis concept. Toxicology, 181-182, 471-474.
26. Kerr, J.F., Winterford, C.M. and Harmon, B.V. (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer, 73, 2013-2026.
27. Pirnia, F., Scheneider, E., Betticher, D.C. and Borner, M.M. (2002) Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. Cell Death Differ., 9, 905-914.
28. Cohen, G.M. (1997) Caspases: the executioners of apoptosis. Biochem. J., 326, 1-16.
29. Srinivasula, S.M., Ahmad, M., Fernandez-Alnemri, T., Litwack, G. and Alnemri, E.S. (1996) Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl Acad Sci. USA, 93, 14486-14491.
30. Felik, S.W. (2000) Insights into programmed cell death through structural biology. Cell, 103, 273-282.
31. Srinivasula, S.M., Ahmad, M., Fernandez-Alnemri, T. and Alnemri, E.S. (1998) Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell, 1, 949-957.
32. Pan J., Xu, G. and Yeung, J.S.C. (2001) Cytocrome c release is upstream to activation of caspase-9, caspase-8 and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J. Clin. Endocrinol. Metab., 86, 4731-4740.
33. Wesselborg, S., Engels, H.I., Rossmann, E., Los, M. and Ostholff-Schulze, K. (1999) Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood, 93, 3053-3063.
34. Schimnich, A.A, Pietras, E.M, Barnhar, B.C., Legembre, P., Vijayan, S., Holbech, S.L. and Peter, M.E. (2003) Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc. Natl Acad. Sci. USA, 100, 11445-11450.
35. Barnhart, B.C., Pietras, E.M., Algeciras-Schimnich, A., Salmena, L., Sayama, K., Hakem, R. and Peter, M.E. (2004) CD95 apoptosis resistance in certain cells can be overcome by noncanonical activation of caspase-8. Cell Death Differ., 1-13.
36. Debatin, K.M. and Krammer, P.H. (2004) Death receptors in chemotherapy and cancer. Oncogene, 23, 2950-2966.